GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $25.42 and traded as low as $22.73. GENMAB A/S/S shares last traded at $23.12, with a volume of 2,491,240 shares.
GENMAB A/S/S Stock Performance
The company’s 50 day moving average is $25.42 and its 200-day moving average is $26.89.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Stories
- Five stocks we like better than GENMAB A/S/S
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Canadian Penny Stocks: Can They Make You Rich?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Using the MarketBeat Dividend Yield Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
